The FDA has approved Teva’s ProAir HFA albuterol metered dose inhaler with a dose counter for the treatment and prevention of bronchospasm in patients 4 years of age and older. According to the company, the new product will be available by the end of 2012.
Teva Global Respiratory Research and Development Senior VP Tushar Shah explained: “The dose counter is designed to help patients, as well as their healthcare providers, keep track of the number of doses remaining in the inhaler. Patients prescribed ProAir HFA will continue to receive their standard inhaler until we launch this important advancement. Short-Acting Beta-Agonists like ProAir are an essential component of clinical treatment guidelines for asthma, COPD and EIB.”
The ProAir HFA MDI was first approved by the FDA in 2004.
Read the Teva press release.
